<?xml version="1.0" encoding="UTF-8"?>
<p id="para2450">In New Zealand, NAFLD is also gaining prominence as a cause of liver mortality. According to the GHE 2015 dataset, NAFLD and other causes accounted for 7·6% of all deaths due to cirrhosis and other chronic liver diseases, and for 6·8% of all deaths due to liver cancer (
 <xref rid="tbl2" ref-type="table">table 2</xref>).
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> The prevalence of obesity in New Zealand has also drastically increased since 1990 (10% in men and 13% in women for that year).
 <xref rid="bib233" ref-type="bibr">
  <sup>233</sup>
 </xref> The New Zealand Health Survey Results for 2015–16 indicate that almost one in three adults (aged 15 years and older) were obese (32%) and a further 35% of adults were overweight.
 <xref rid="bib234" ref-type="bibr">
  <sup>234</sup>
 </xref> Health-care costs attributable to obesity were estimated to be NZ$686 million (4·5% of New Zealand's total health-care expenditure in 2006), or $911 million when lost productivity was included. Data on liver enzymes as indirect indices of NAFLD from a nutritional survey of more than 4721 New Zealanders aged 15 years and older indicated that the prevalence of increased concentrations of alanine aminotransferase and γ-glutamyltransferase was approximately 13% for 2008–09.
 <xref rid="bib235" ref-type="bibr">
  <sup>235</sup>
 </xref>
</p>
